Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02547935
Recruitment Status : Completed
First Posted : September 14, 2015
Results First Posted : June 4, 2019
Last Update Posted : August 21, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and renal impairment (CKD). The study is planned to randomize a total of 450 patients (150 patients per treatment arm)

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus, CKD and Albuminuria Drug: Dapagliflozin 10 mg Drug: Saxagliptin 2.5 mg Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 459 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: An Exploratory Phase II/III, Randomized, Double-blind, Placebo Controlled, Parallel Design Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Dapagliflozin and Dapagliflozin in Combination With Saxagliptin in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria Treated With ACEi or ARB
Actual Study Start Date : September 21, 2015
Actual Primary Completion Date : May 18, 2018
Actual Study Completion Date : May 18, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dapagliflozin 10mg
Tablets administered orally once daily for 24 weeks
Drug: Dapagliflozin 10 mg
Tablets administered orally once daily for 24 weeks.
Other Name: Forxiga™

Experimental: Dapagliflozin 10mg + Saxagliptin 2.5mg
Tablets administered orally once daily for 24 weeks
Drug: Saxagliptin 2.5 mg
Tablets administered orally once daily for 24 weeks.
Other Name: Onglyza™

Placebo Comparator: Placebo
Tablets administered orally once daily for 24 weeks
Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Tablets administered orally once daily for 24 weeks.




Primary Outcome Measures :
  1. Adjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c): Comparison of Dapagliflozin 10 mg Plus Saxagliptin 2.5 mg and Placebo at Week 24 [ Time Frame: Baseline and Week 24 ]
    HbA1c was analysed at baseline and every 4 weeks during the 24-week treatment period. Only measurements prior to rescue or treatment discontinuation were analysed. The adjusted mean change from baseline at Week 24 was analysed using a mixed model repeated measures (MMRM) model.

  2. Adjusted Mean Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24 [ Time Frame: Baseline and Week 24 ]
    UACR was analysed at baseline and every 4 weeks during the 24-week treatment period. All measurements regardless of rescue medication or treatment discontinuation were analysed. UACR values were first transformed to logarithms and the results were based on exponentiation of model estimates and expressed as adjusted mean percent change from baseline at Week 24.


Secondary Outcome Measures :
  1. Adjusted Mean Percent Change From Baseline in Total Body Weight at Week 24 [ Time Frame: Baseline and Week 24 ]
    Total body weight was measured in kilograms (kg) at baseline and at Week 1 then every 4 weeks during the 24-week treatment period. All measurements regardless of rescue medication or treatment discontinuation were analysed. Total body weight values were first transformed to logarithms and the results were based on exponentiation of model estimates and expressed as adjusted mean percent change from baseline at Week 24.

  2. Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 [ Time Frame: Baseline and Week 24 ]
    FPG was analysed at baseline and Week 1 then every 4 weeks during the 24-week treatment period. Only measurements prior to rescue or treatment discontinuation were analysed. The adjusted mean change from baseline at Week 24 was analysed using a MMRM model.

  3. Percentage of Patients Achieving at Least 30% Reduction in UACR at Week 24 [ Time Frame: From baseline up to Week 24 ]
    The percentage of patients meeting the criteria of at least a 30% reduction in UACR, was analysed using a logistic regression model. If no measurement was available at Week 24 the last available post-baseline measurement was carried forward (Last Observation Carried Forward [LOCF]).

  4. Percentage of Patients Achieving a Reduction in HbA1c of Less Than 7.0% at Week 24 [ Time Frame: From baseline to Week 24 ]
    The percentage of patients meeting the criteria of a less than 7% reduction in HbA1c, was analysed using a logistic regression model. If no measurement was available at Week 24 the last available post-baseline measurement was carried forward (LOCF). Only measurements prior to rescue or treatment discontinuation were analysed.

  5. Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24 [ Time Frame: Baseline and Week 24 ]
    Seated SBP was analysed at baseline, Week 1 and every 4 weeks during the 24-week treatment period. All measurements regardless of rescue medication or treatment discontinuation were analysed. The adjusted mean change from baseline at Week 24 was analysed using a MMRM model.

  6. Adjusted Mean Change From Baseline in HbA1c: Comparison of Dapagliflozin 10 mg and Placebo at Week 24 [ Time Frame: Baseline and Week 24 ]
    HbA1c was analysed at baseline and every 4 weeks during the 24-week treatment period. Only measurements prior to rescue or treatment discontinuation were analysed. The adjusted mean change from baseline at Week 24 was analysed using a MMRM model.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of informed consent prior to any study specific procedures
  • Female or male aged ≥18 years
  • History of type 2 diabetes mellitus for more than 12 months
  • HbA1c≥7.0% and ≤11.0%
  • Stable antidiabetic treatment during the last 12 weeks up to randomization
  • eGFR 25-75 mL/minute/1.73m2, inclusive
  • Micro or macroalbuminuria (UACR 30 - 3500 mg/g)
  • Treatment with ACE inhibitor or an ARB for at least 3 months prior to screening
  • Body mass index between 20 and 45 kg/m2

Exclusion Criteria:

  • Any of the following CV/Vascular Diseases within 3 month prior to signing the consent at Visit 1:

    • Myocardial infarction
    • cardiac surgery or revascularization (CABG/PTCA)
    • unstable angina
    • unstable HF
    • New York Heart Association (NYHA) Class III-IV
    • transient ischemic attack (TIA) or significant cerebrovascular disease
    • unstable or previously undiagnosed arrhythmia
  • Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency
  • Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) > 3X ULN
  • Total Bilirubin (TB) >2 mg/dL (34.2 μmol/L)
  • History of acute kidney injury requiring renal replacement therapy (dialysis or ultrafiltration) or any biopsy or imaging verifying intercurrent kidney disease other than diabetic nephropathy or diabetic nephropathy with nephrosclerosis
  • Ongoing treatment with a SGLT2 inhibitor, GLP-1 agonist or DPP4 inhibitors
  • Any condition which, in the judgment of the Investigator, may render the patient unable to complete the study or which may pose a significant risk to the patient or patient suspected or with confirmed poor protocol or medication compliance

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02547935


Locations
Hide Hide 112 study locations
Layout table for location information
United States, Arizona
Research Site
Peoria, Arizona, United States, 85381
United States, California
Research Site
Chula Vista, California, United States, 91910
Research Site
Concord, California, United States, 94520
Research Site
El Centro, California, United States, 92243
Research Site
La Mesa, California, United States, 92123
Research Site
Long Beach, California, United States, 90807
Research Site
Los Gatos, California, United States, 95032
Research Site
North Hollywood, California, United States, 91606
Research Site
Riverside, California, United States, 92505
Research Site
San Diego, California, United States, 92111
Research Site
San Dimas, California, United States, 91773
United States, Florida
Research Site
Hollywood, Florida, United States, 33024
Research Site
Miami, Florida, United States, 33126
Research Site
New Port Richey, Florida, United States, 34652
Research Site
Palm Harbor, Florida, United States, 34684
Research Site
Pompano Beach, Florida, United States, 33060
United States, Georgia
Research Site
Augusta, Georgia, United States, 30909
United States, Idaho
Research Site
Meridian, Idaho, United States, 83642
United States, Illinois
Research Site
Chicago, Illinois, United States, 60643
United States, Maine
Research Site
Bangor, Maine, United States, 04401
United States, Missouri
Research Site
Kansas City, Missouri, United States, 64111
United States, Nevada
Research Site
Las Vegas, Nevada, United States, 89148
United States, New York
Research Site
Bronx, New York, United States, 10459
Research Site
Springfield Gardens, New York, United States, 11413
United States, North Carolina
Research Site
Greensboro, North Carolina, United States, 27408
Research Site
Morehead City, North Carolina, United States, 28557
Research Site
Rocky Mount, North Carolina, United States, 27804
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States, 19107
United States, South Carolina
Research Site
Greenville, South Carolina, United States, 29605
United States, Texas
Research Site
Brownsville, Texas, United States, 78520
Research Site
Cypress, Texas, United States, 77429
Research Site
Houston, Texas, United States, 77004
Research Site
San Antonio, Texas, United States, 78215
Research Site
Sugar Land, Texas, United States, 77479
United States, Utah
Research Site
Salt Lake City, Utah, United States, 84124
United States, Virginia
Research Site
Burke, Virginia, United States, 22015
Research Site
Richmond, Virginia, United States, 23219
Australia
Research Site
Box Hill, Australia, 3128
Research Site
Campbelltown, Australia, 2560
Research Site
Geelong, Australia, 3220
Research Site
Herston, Australia, 4029
Canada, Manitoba
Research Site
Winnipeg, Manitoba, Canada, R3E 3P4
Canada, New Brunswick
Research Site
Moncton, New Brunswick, Canada, E1G 1A7
Canada, Ontario
Research Site
Ajax, Ontario, Canada, L1Z 0M1
Research Site
Cambridge, Ontario, Canada, N1R 6V6
Research Site
Scarborough, Ontario, Canada, M1H 3G4
Research Site
Scarborough, Ontario, Canada, M1R 3A6
Research Site
Toronto, Ontario, Canada, M5C 2T2
Canada, Quebec
Research Site
Chicoutimi, Quebec, Canada, G7H 7K9
Research Site
Saint-Jerome, Quebec, Canada, J7Z 5T3
Research Site
Sherbrooke, Quebec, Canada, J1H 5N4
Canada
Research Site
Quebec, Canada, G2J 0C4
Japan
Research Site
Chuo-ku, Japan, 103-0002
Research Site
Chuo-ku, Japan, 103-0027
Research Site
Chuo-ku, Japan, 103-0028
Research Site
Hachioji-shi, Japan, 192-0071
Research Site
Higashiosaka-shi, Japan, 577-0803
Research Site
Kisarazu-shi, Japan, 292-0038
Research Site
Kyoto-shi, Japan, 615-8125
Research Site
Neyagawa-shi, Japan, 572-0015
Research Site
Nishinomiya-shi, Japan, 663-8113
Research Site
Oita-shi, Japan, 870-0039
Research Site
Osaka-shi, Japan, 530-0001
Research Site
Osaka-shi, Japan, 559-0012
Research Site
Sendai-shi, Japan, 980-0021
Research Site
Shinjuku-ku, Japan, 160-0008
Research Site
Toyonaka-shi, Japan, 560-0082
Korea, Republic of
Research Site
Ansan-si, Korea, Republic of, 15355
Research Site
Busan, Korea, Republic of, 47392
Research Site
Cheongju-si, Korea, Republic of, 28644
Research Site
Daejeon, Korea, Republic of, 35015
Research Site
Seongnam-si, Korea, Republic of, 13620
Research Site
Seoul, Korea, Republic of, 02841
Research Site
Seoul, Korea, Republic of, 03080
Research Site
Seoul, Korea, Republic of, 06351
Research Site
Suwon-si, Korea, Republic of, 16499
Research Site
Wonju-si, Korea, Republic of, 26426
Mexico
Research Site
Aguascalientes, Mexico, 20230
Research Site
Guadalajara, Mexico, 44160
Research Site
Guadalajara, Mexico, 44600
Research Site
Guadalajara, Mexico, 44670
Research Site
Mexico, Mexico, 03800
Research Site
Mexico, Mexico, 06726
Research Site
Monterey, Mexico, 64060
Research Site
Monterrey, Mexico, 64460
Research Site
Monterrey, Mexico, 64465
Research Site
México, Mexico, 03300
Research Site
Queretaro, Mexico, 76000
Research Site
Zapopan, Jalisco, Mexico, 45200
Research Site
Zapopan, Mexico, 45116
South Africa
Research Site
Benoni, South Africa, 1501
Research Site
Cape Town, South Africa, 1730
Research Site
Cape Town, South Africa, 7925
Research Site
Durban, South Africa, 4092
Research Site
Kuilsrivier, South Africa, 7580
Research Site
Mamelodi East, South Africa, 0184
Research Site
Muckleneuk, South Africa, 0002
Research Site
Paarl, South Africa, 7646
Research Site
Pretoria, South Africa, 184
Spain
Research Site
A Coruña, Spain, 15006
Research Site
Barcelona, Spain, 08035
Research Site
Madrid, Spain, 28046
Research Site
Sabadell (Barcelona), Spain, 08208
Research Site
Santiago(A Coruña), Spain, 15706
Research Site
Valencia, Spain, 46017
Taiwan
Research Site
Changhua, Taiwan, 500
Research Site
Kaohsiung Hsien, Taiwan, 83342
Research Site
New Taipei City, Taiwan, 23148
Research Site
New Taipei, Taiwan
Research Site
Taichung, Taiwan, 40705
Research Site
Taipei City, Taiwan, 112
Research Site
Yong-Kang City, Taiwan, 71004
Sponsors and Collaborators
AstraZeneca
  Study Documents (Full-Text)

Documents provided by AstraZeneca:
Study Protocol  [PDF] September 18, 2017
Statistical Analysis Plan  [PDF] June 5, 2018


Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02547935    
Other Study ID Numbers: D1690C00023
First Posted: September 14, 2015    Key Record Dates
Results First Posted: June 4, 2019
Last Update Posted: August 21, 2019
Last Verified: July 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Albuminuria
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Proteinuria
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Saxagliptin
Sodium-Glucose Transporter 2 Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors